Top

Published in:

01-03-2010 | Original Contribution

Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats

Authors: Claudia Penna, Francesca Tullio, Francesca Moro, Anna Folino, Annalisa Merlino, Pasquale Pagliaro

Published in: Basic Research in Cardiology | Issue 2/2010

Abstract

Brief periods (a few seconds) of cyclic coronary occlusions applied early in reperfusion induce a cardioprotection against infarct size, called postconditioning (PostC) in which B₂-bradykinin receptors play a pivotal role. Since angiotensin-converting enzyme (ACE) inhibitors reduce degradation of kinins, we studied the effects of PostC on infarct size and postischemic myocardial dysfunction in both normotensive (WKY) and spontaneously hypertensive rats (SHR) acutely or chronically treated with the ACE inhibitor Captopril. Isolated hearts from SHR and WKY rats were subjected to the following protocols: (a) ischemia for 30- and 120-min reperfusion (I/R); (b) I/R + PostC protocol (5-cycles 10-s I/R); (c) pretreatment with Captopril for 4-weeks before to subject the hearts to I/R with or without PostC maneuvers. Some SHR hearts were treated with Captopril during the 20- or 40-min early reperfusion with or without PostC maneuvers. Cardiac function was assessed in vivo with echocardiography. Left ventricular pressure and infarct size were measured ex vivo. Chronic Captopril significantly reduced left ventricular hypertrophy in SHR, and reduced infarct size in both WKY and SHR hearts. PostC maneuvers significantly reduced infarct size in WKY, but not in SHR hearts. Yet, PostC slightly improved postischemic systolic function in untreated SHR. Captopril given in reperfusion was unable to limit I/R injury in SHR hearts. Data show that PostC protection against infarct size is blunted in SHR and that PostC is unable to add its protective effect to those of chronic Captopril, which per se reduces cardiac hypertrophy and heart susceptibility to I/R insult.

Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI (2006) Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 290:H684–H691CrossRefPubMed

Benzing T, Fleming I, Blaukat A, Müller-Esterl W, Busse R (1999) Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 99:2034–2040PubMed

Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, Schulz R (2008) Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102:131–135CrossRefPubMed

Boengler K, Schulz R, Heusch G (2009) Loss of cardioprotection with ageing. Cardiovasc Res 83:247–261CrossRefPubMed

Cohen MV, Yang XM, Liu GS, Heusch G, Downey JM (2001) Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial KATP channels. Circ Res 89:273–278CrossRefPubMed

Das DK, Maulik N, Engelman RM (2004) Redox regulation of angiotensin II signaling in the heart. J Cell Mol Med 8:144–152CrossRefPubMed

Delles C, Schneider MP, John S, Gekle M, Schmieder RE (2002) Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 15:590–593CrossRefPubMed

Ebrahim Z, Yellon DM, Baxter GF (2007) Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension. Exp Gerontol 42:807–814CrossRefPubMed

Evangelista S, Manzini S (2005) Antioxidant and cardioprotective properties of the sulphydryl angiotensinconverting enzyme inhibitor zofenopril. The J of Intern Med Res 33:42–54

10.

Fantinelli JC, Mosca SM (2007) Comparative effects of ischemic pre and postconditioning on ischemia-reperfusion injury in spontaneously hypertensive rats (SHR). Mol Cell Biochem 296:45–51CrossRefPubMed

11.

Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59:418–458CrossRefPubMed

12.

Fiordaliso F, Cuccovillo I, Bianchi R, Bai A, Doni M, Salio M, De Angelis N, Ghezzi P, Latini R, Masson S (2006) Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci 79:121–129CrossRefPubMed

13.

Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575–1581CrossRefPubMed

14.

Fleming I (2006) Signaling by the angiotensin-converting enzyme. Circ Res 98:887–896CrossRefPubMed

15.

Gardin JM, Siri F, Kitsis RN, Leinwand L (1996) Intravascular ultrasound catheter evaluation of the left ventricle in mice: a feasibility study. Echocardiography 13:609–612CrossRefPubMed

16.

Granfeldt A, Lefer DJ, Vinten-Johansen J (2009) Protective ischemia in patients: preconditioning and postconditioning. Cardiovasc Res 83:234–246CrossRefPubMed

17.

Hausenloy DJ, Ong SB, Yellon DM (2009) The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 104:189–202CrossRefPubMed

18.

Hausenloy DJ, Tsang A, Yellon DM (2005) The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15:69–75CrossRefPubMed

19.

Heusch G (2004) Postconditioning: old wine in a new bottle? J Am Coll Cardiol 44:1111–1112CrossRefPubMed

20.

Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118:1915–1919CrossRefPubMed

21.

Hilgenfeldt U, Stannek C, Lukasova M, Schnolzer M, Lewicka S (2005) Rat tissue kallikrein releases a kallidin-like peptide from rat low-molecular-weight kininogen. Br J Pharmacol 146:958–963CrossRefPubMed

22.

Iliodromitis EK, Downey JM, Heusch G, Kremastinos DT (2009) What is the optimal postconditioning algorithm? J Cardiovasc Pharmacol Ther 14:269–273CrossRefPubMed

23.

Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, Zhao ZQ, Guyton RA, Headrick JP, Vinten-Johansen J (2005) Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67:124–133CrossRefPubMed

24.

Kohlstedt K, Brandes RP, Muller-Esterl W, Busse R, Fleming I (2004) Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res 94:60–67CrossRefPubMed

25.

Liu X, Lukasova M, Zubakova R, Lewicka S, Hilgenfeldt U (2005) A kallidin-like peptide is a protective cardiac kinin, released by ischaemic preconditioning of rat heart. Br J Pharmacol 146:952–927

26.

Liu X, Lukasova M, Zubakova R, Lewicka S, Hilgenfeldt U (2006) Kallidin-like peptide mediates the cardioprotective effect of the ACE inhibitor captopril against ischaemic reperfusion injury of rat heart. Br J Pharmacol 148:825–832CrossRefPubMed

27.

Ludbrook J (1994) Repeated measurements and multiple comparison in cardiovascular research. Cardiovasc Res 28:301–311CrossRef

28.

Marktanner R, Nacke P, Feindt P, Hohlfeld T, Schipke JD, Gams E (2006) Delayed preconditioning via Angiotensin-converting enzyme inhibition: pros and cons from an experimental study. Clin Exp Pharmacol Physiol 33:787–792CrossRefPubMed

29.

Miura T, Miki T (2008) Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 103:501–513CrossRefPubMed

30.

Morris SD, Yellon DM (1997) Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J Am Coll Cardiol 29:1599–1606CrossRefPubMed

31.

Norton GR, Veliotes DG, Osadchii O, Woodiwiss AJ, Thomas DP (2008) Susceptibility to systolic dysfunction in the myocardium from chronically infarcted spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 294:H372–H378CrossRefPubMed

32.

Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD, Cohen MV, Downey JM (2004) Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol 286:H468–H476CrossRefPubMed

33.

Oldenburg O, Qin Q, Sharma AR, Cohen MV, Downey JM, Benoit JN (2002) Acetylcholine leads to free radical production dependent on KATP channels, Gi proteins, phosphatidylinositol 3-kinase and tyrosine kinase. Cardiovasc Res 55:544–552CrossRefPubMed

34.

Pagliaro P, Mancardi D, Rastaldo R, Penna C, Gattullo D, Miranda KM, Feelisch M, Wink DA, Kass DA, Paolocci N (2003) Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med 34:33–43CrossRefPubMed

35.

Pagliaro P, Penna C (2005) Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther 19:77–87CrossRefPubMed

36.

Papaioannou VE, Fox JG (1993) Efficacy of tribromoethanol anesthesia in mice. Lab Anim Sci 43:189–192PubMed

37.

Peart JN, Gross ER, Reichelt ME, Hsu A, Headrick JP, Gross GJ (2008) Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts. Basic Res Cardiol 103:454–463CrossRefPubMed

38.

Penna C, Cappello S, Mancardi D, Raimondo S, Rastaldo R, Gattullo D, Losano G, Pagliaro P (2006) Post-conditioning reduces infarct size in the isolated rat heart: role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 101:168–179CrossRefPubMed

39.

Penna C, Mancardi D, Raimondo S, Geuna S, Pagliaro P (2008) The paradigm of postconditioning to protect the heart. J Cell Mol Med 12:435–458CrossRefPubMed

40.

Penna C, Mancardi D, Rastaldo R, Losano G, Pagliaro P (2007) Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res 75:168–177CrossRefPubMed

41.

Penna C, Mancardi D, Rastaldo R, Pagliaro P (2009) Cardioprotection: a radical view Free radicals in pre and postconditioning. Biochim Biophys Acta 1787:781–793CrossRefPubMed

42.

Penna C, Mancardi D, Tullio F, Pagliaro P (2008) Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 103:368–377CrossRefPubMed

43.

Penna C, Mancardi D, Tullio F, Pagliaro P (2009) Intermittent adenosine at the beginning of reperfusion does not trigger cardioprotection. J Surg Res 153:231–238CrossRefPubMed

44.

Penna C, Mognetti B, Tullio F, Gattullo D, Mancardi D, Moro F, Pagliaro P, Alloatti G (2009) Post-ischaemic activation of kinases in the pre-conditioning-like cardioprotective effect of the platelet-activating factor. Acta Physiol (Oxf) 197:175–185CrossRef

45.

Penna C, Mognetti B, Tullio F, Gattullo D, Mancardi D, Pagliaro P, Alloatti G (2008) The platelet activating factor triggers preconditioning-like cardioprotective effect via mitochondrial K-ATP channels and redox-sensible signaling. J Physiol Pharmacol 59:47–54PubMed

46.

Penna C, Perrelli MG, Raimondo S, Tullio F, Merlino A, Moro F, Geuna S, Mancardi D, Pagliaro P (2009) Postconditioning induces an anti-apoptotic effect and preserves mitochondrial integrity in isolated rat hearts. Biochim Biophys Acta 1787:794–801CrossRefPubMed

47.

Penna C, Rastaldo R, Mancardi D, Raimondo S, Cappello S, Gattullo D, Losano G, Pagliaro P (2006) Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K + channel and protein kinase C activation. Basic Res Cardiol 101:180–189CrossRefPubMed

48.

Penna C, Tullio F, Merlino A, Moro F, Raimondo S, Rastaldo R, Perrelli MG, Mancardi D, Pagliaro P (2009) Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender. Basic Res Cardiol 104:390–402CrossRefPubMed

49.

Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E (1982) Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci USA 79:3310–3314CrossRefPubMed

50.

Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677PubMedCrossRef

51.

Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV (2006) Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res 70:308–314CrossRefPubMed

52.

Remme WJ (2003) Should ACE inhibition always be first-line therapy in heart failure? Lessons from the CARMEN Study. Cardiovasc Drugs Ther 17:107–109CrossRefPubMed

53.

Schulz R, Post H, Vahlhaus C, Heusch G (1998) Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. Circulation 98:1022–1029PubMed

54.

Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G (2009) Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol 104:469–483CrossRefPubMed

55.

Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L’Huillier I, Aupetit JF, Bonnefoy E, Finet G, André-Fouët X, Ovize M (2005) Postconditioning the human heart. Circulation 112:2143–2148CrossRefPubMed

56.

Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004) Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95:230–232CrossRefPubMed

57.

Wall TM, Sheehy R, Hartman JC (1994) Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 270:681–689PubMed

58.

Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G (2000) Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br J Pharmacol 131:138–144CrossRefPubMed

59.

Xi L, Das A, Zhao ZQ, Merino VF, Bader M, Kukreja RC (2008) Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice. Circulation 118:S32–S37CrossRefPubMed

60.

Yang XM, Krieg T, Cui L, Downey JM, Cohen MV (2004) NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3 K, ERK, and NO. J Mol Cell Cardiol 36:411–421CrossRefPubMed

61.

Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV (2004) Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44:1103–1110CrossRefPubMed

62.

Yang XP, Liu YH, Scicli GM, Webb CR, Carretero OA (1997) Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 30:735–740PubMed

63.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153CrossRefPubMed

64.

Zahler S, Kupatt C, Becker BF (1999) ACE-inhibition attenuates cardiac cell damage and preserves release of NO in the postischemic heart. Immunopharmacology 44:27–33CrossRefPubMed

65.

Zhao HX, Wang XL, Wang YH, Wu Y, Li XY, Lv XP, Zhao ZQ, Zhao RR, Liu HR (2009) Attenuation of myocardial injury by postconditioning: role of hypoxia inducible factor-1alpha. Basic Res Cardiol. doi:10.1007/s00395-009-0044-0

66.

Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285:H579–H588 (Erratum in: Am J Physiol Heart Circ Physiol 2004; 286: H477)

67.

Zhu M, Feng J, Lucchinetti E, Fischer G, Xu L, Pedrazzini T, Schaub MC, Zaugg M (2006) Ischemic postconditioning protects remodeled myocardium via the PI3 K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res 72:152–162CrossRefPubMed

Title: Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats
Authors: Claudia Penna
Francesca Tullio
Francesca Moro
Anna Folino
Annalisa Merlino
Pasquale Pagliaro
Publication date: 01-03-2010
Publisher: D. Steinkopff-Verlag
Published in: Basic Research in Cardiology / Issue 2/2010
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-009-0075-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition

Anti-inflammatory effect of oxytocin in rat myocardial infarction

Aldosterone improves contractile function of adult rat ventricular cardiomyocytes in a non-acute way: potential relationship to the calcium paradox of aldosteronism

Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection

Nitric oxide/cGMP signalling mediates the cardioprotective action of adrenomedullin in reperfused myocardium

K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page